PERTH, AUSTRALIA, January 24, 2011 - Phylogica Ltd
(ASX:PYC), (XETRA:PH7), a leading Australian drug discovery company, announced today that it has received the 2011 Asia Pacific Frost & Sullivan New Product Innovation Award for Peptide Screening Technologies for its Phylomer® platform. This prestigious award underscores Phylogica’s leadership in realising the untapped potential of nature’s vast biodiversity to discover novel peptide-based drugs.
Frost & Sullivan is a global growth consulting company and it presents these awards to companies demonstrating measured excellence and technological advancement within their field across a variety of regional and global markets.
In bestowing this award to Phylogica, Frost & Sullivan highlighted the Company’s expertise in peptide screening and also the uniqueness of its Phylomer peptide libraries. These libraries compromise billions of natural peptides derived from an evolutionary diverse range of microbial genomes. Phylogica has integrated its Phylomer libraries with a suite of high-throughput screening technologies to create an
efficient drug discovery platform based on the world’s most structurally diverse peptide libraries.
Phylogica’s Chief Executive Officer, Dr Paul Watt, said: "We are proud to have received this award from Frost & Sullivan, which is further acknowledgment that our Phylomer platform is at the forefront of peptide drug discovery. Phylogica is gaining increasing recognition within the pharmaceutical industry as a valued collaborative partner with world-class technology. There is growing interest in peptide therapeutics for the treatment of a wide range of diseases and we are well positioned to take
advantage of these market dynamics to accelerate our growth.”
-ends-
